High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Current standard treatments for lymphoma involving the central nervous system include
chemotherapy or whole brain radiation therapy (WBRT). However, many patients do not respond
to this treatment, and some of the patients who do respond relapse after treatment.
Previous research has shown that a stem cell transplant of a patient's own cells (autologous
stem cell transplant) may be more effective for some patients with lymphoma involving the
CNS. In previous research using autologous stem cell transplants for lymphoma involving the
CNS, a conditioning regimen consisting of the drugs thiotepa, busulfan and cyclophosphamide
(TCE) was used. These drugs have been shown to enter the nervous system.
In this research study, the investigators are adding the drug rituximab (Rituxan) to the drug
cytarabine for the stem cell mobilization process. Cytarabine is a standard drug for
mobilization. In addition, rituximab will be added to the conditioning regimen of thiotepa,
busulfan and cyclophosphamide. Rituximab is approved by the FDA for the treatment of some
types of lymphomas, but is not approved for use in lymphomas that involve the CNS. Rituximab
is known to be able to enter the CNS. Previous research has suggested that it may help treat
lymphoma that involves the CNS.
The goal of this research study is to see if adding rituximab to the stem cell mobilization
and conditioning regimens helps treat lymphoma that involves the central nervous system.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Dana-Farber Cancer Institute Genentech, Inc. Otsuka America Pharmaceutical